Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Discovery of a Highly Potent and Broadly Effective Epidermal Growth Factor Receptor and HER2 Exon 20 Insertion Mutant Inhibitor.

Angewandte Chemie (International ed. in English) - 3 Sept 2018

Jang Jaebong, Son Jieun, Park Eunyoung, Kosaka Takayuki, Saxon Jamie A, De Clercq Dries J H, Choi Hwan Geun, Tanizaki Junko, Eck Michael J, Jänne Pasi A, Gray Nathanael S

Abstract excerpt

Exon 20 insertion (Ex20Ins) mutations are the third most prevalent epidermal growth factor receptor (EGFR) activating mutation and the most prevalent HER2 mutation in non-small cell lung cancer (NSCLC). Novel therapeutics for the patients with Ex20Ins mutations are urgently needed, due to their poor responses to the currently approved EGFR and HER2 inhibitors. Here we report the discovery of highly potent and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell Line, Tumor
Share to Cell Proliferation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to ErbB Receptors

Share to Lung Neoplasms

Share to Molecular Docking Simulation

Share to Protein Kinase Inhibitors

Share to Receptor, ErbB-2

Source

Open in PubMed Open full text

Identifiers

PMID: 29978938
DOI: 10.1002/anie.201805187
PMCID: PMC6118895

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Discovery of a Highly Potent and Broadly Effective Epidermal Growth Factor Receptor and HER2 Exon 20 Insertion Mutant Inhibitor.PMID 29978938Read ↗

Structural Mechanism and Inhibitors Targeting EGFR Exon 20 Insertion (Ex20ins) Mutations.Semantic proximity Read ↗

The current landscape, advancements, and prospects in the treatment of patients with EGFR exon 20 insertion mutations warrant scientific elucidationSemantic proximity Read ↗

Novel drugs targeting EGFR and HER2 exon 20 mutations in metastatic NSCLC.Semantic proximity Read ↗

Discovery of YK-029A, a novel mutant EGFR inhibitor targeting both T790 M and exon 20 insertion mutations, as a treatment for NSCLC.Semantic proximity Read ↗

Discovery of STX-721, a Covalent, Potent, and Highly Mutant-Selective EGFR/HER2 Exon20 Insertion Inhibitor for the Treatment of Non-Small Cell Lung CancerSemantic proximity Read ↗

Current status and breakthroughs in treating advanced non-small cell lung cancer with EGFR exon 20 insertion mutations.Semantic proximity Read ↗

EGFR exon 20 insertion mutations in non-small cell lung cancerSemantic proximity Read ↗

Therapeutic Advances in Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations: From Molecular Biology to Targeted Therapy.Semantic proximity Read ↗

Advances in the Diagnosis and Treatment of Advanced Non-Small-Cell Lung Cancer With EGFR Exon 20 Insertion Mutation.Semantic proximity Read ↗

Insight into Targeting Exon20 Insertion Mutations of the Epidermal Growth Factor Receptor with Wild Type-Sparing Inhibitors.Semantic proximity Read ↗

STX-721, a Covalent EGFR/HER2 Exon 20 Inhibitor, Utilizes Exon 20–Mutant Dynamic Protein States and Achieves Unique Mutant Selectivity Across Human Cancer ModelsSemantic proximity Read ↗

Structure optimization and discovery of novel compound for the treatment of insertion mutations within exon 20 of EGFR and HER2.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.